Barclays
ABUS icon

Barclays’s Arbutus Biopharma ABUS Stock Holding History

Barclays’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4M Buy
4,316,095
+3,959,411
+1,110% +$17.3M ﹤0.01% 1118
2025
Q4 		$1.72M Buy
356,684
+72,354
+25% +$325K ﹤0.01% 3049
2025
Q3 		$1.29M Sell
284,330
-122,228
-30% -$449K ﹤0.01% 3210
2025
Q2 		$1.26M Buy
406,558
+180,393
+80% +$599K ﹤0.01% 3176
2025
Q1 		$789K Sell
226,165
-72,088
-24% -$240K ﹤0.01% 3250
2024
Q4 		$975K Buy
298,253
+26,224
+10% +$96.5K ﹤0.01% 3396
2024
Q3 		$1.05M Buy
272,029
+223,995
+466% +$859K ﹤0.01% 3324
2024
Q2 		$148K Sell
48,034
-41,152
-46% -$123K ﹤0.01% 3730
2024
Q1 		$230K Sell
89,186
-126,757
-59% -$328K ﹤0.01% 4049
2023
Q4 		$540K Buy
215,943
+84,098
+64% +$165K ﹤0.01% 3824
2023
Q3 		$268K Buy
131,845
+83,950
+175% +$176K ﹤0.01% 3145
2023
Q2 		$110K Sell
47,895
-9,663
-17% -$25.2K ﹤0.01% 3518
2023
Q1 		$174K Buy
57,558
+27,054
+89% +$76.3K ﹤0.01% 3872
2022
Q4 		$71.1K Buy
30,504
+25,925
+566% +$62K ﹤0.01% 4413
2022
Q3 		$9K Sell
4,579
-841
-16% -$1.98K ﹤0.01% 4337
2022
Q2 		$15K Sell
5,420
-329,376
-98% -$843K ﹤0.01% 4495
2022
Q1 		$997K Buy
334,796
+63,342
+23% +$194K ﹤0.01% 2401
2021
Q4 		$1.05M Sell
271,454
-364,002
-57% -$1.41M ﹤0.01% 2800
2021
Q3 		$2.73M Buy
635,456
+625,543
+6,310% +$2.08M ﹤0.01% 2092
2021
Q2 		$30K Sell
9,913
-92,956
-90% -$288K ﹤0.01% 4364
2021
Q1 		$342K Buy
102,869
+102,478
+26,209% +$395K ﹤0.01% 3424
2020
Q4 		$1K Buy
+391
New +$1.37K ﹤0.01% 4819
2020
Q1 		– Sell
-360
Closed -$1K – 6104
2019
Q4 		$1K Sell
360
-723
-67% -$1.17K ﹤0.01% 6260
2019
Q3 		$2K Sell
1,083
-73,165
-99% -$126K ﹤0.01% 6533
2019
Q2 		$155K Buy
74,248
+59,103
+390% +$151K ﹤0.01% 5332
2019
Q1 		$54K Buy
15,145
+2,580
+21% +$9.9K ﹤0.01% 5810
2018
Q4 		$48K Sell
12,565
-1,204
-9% -$5.93K ﹤0.01% 5488
2018
Q3 		$130K Buy
13,769
+11,177
+431% +$111K ﹤0.01% 5331
2018
Q2 		$19K Buy
2,592
+2,460
+1,864% +$14.6K ﹤0.01% 6206
2018
Q1 		$1K Sell
132
-72,669
-100% -$385K ﹤0.01% 6938
2017
Q4 		$368K Sell
72,801
-2,940
-4% -$17.2K ﹤0.01% 4143
2017
Q3 		$470K Buy
75,741
+2,941
+4% +$12.6K ﹤0.01% 3693
2017
Q2 		$262K Hold
72,800
– – ﹤0.01% 4149
2017
Q1 		$237K Buy
+72,800
New +$202K ﹤0.01% 4144
2015
Q4 		– Sell
-1
Closed – – 5943
2015
Q3 		$0 Sell
1
-88
-99% -$780 ﹤0.01% 6800
2015
Q2 		$1K Sell
89
-34,729
-100% -$529K ﹤0.01% 6897
2015
Q1 		$592K Buy
34,818
+32,939
+1,753% +$675K ﹤0.01% 3440
2014
Q4 		$28K Buy
+1,879
New +$32.4K ﹤0.01% 6105
2013
Q4 		– Sell
-400
Closed -$2K – 7509
2013
Q3 		$2K Buy
400
+100
+33% +$551 ﹤0.01% 7170
2013
Q2 		$1K Buy
+300
New +$1.42K ﹤0.01% 7589

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's ABUS Position: Q1 2026 in Review

Barclays increased its Arbutus Biopharma (ABUS) stake by 1,110% in Q1 2026, buying an estimated $17.3M and bringing the position to 4,316,095 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

Barclays first reported a position in ABUS in Q2 2013 and has held it in 40 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Barclays held 4,316,095 shares of Arbutus Biopharma worth $19.4M as of Q1 2026.
  • Barclays bought 3,959,411 Arbutus Biopharma shares in Q1 2026, an estimated $17.3M.
  • Arbutus Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1118 holding.
  • Barclays first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 40 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.